Entrada Therapeutics Inc (TRDA) financials
Entrada Therapeutics revenue and earnings by year
Entrada Therapeutics's revenue was $25.4 million in the fiscal year to December 31, 2025, down 87.9% from the year before. Net income was -$144 million, -565.5% of revenue.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 3 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
| Revenue | 25 | 211 | 129 |
| Revenue growth | -87.9% | 63.4% | — |
| Operating income | -158 | 47 | -3 |
| Operating margin | -621.1% | 22.3% | -2.5% |
| Net income | -144 | 66 | -7 |
| Net margin | -565.5% | 31.1% | -5.2% |
| Diluted EPS | -$3.47 | $1.68 | -$0.20 |
| Free cash flow | -130 | -45 | 134 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open TRDA in Markets.
See also: TRDA returns
No forecast, no recommendation. This page describes Entrada Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.